Imlifidase denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for imlifidase are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for Imlifidase — and How to Appeal a Denial

Imlifidase is a highly specialized agent used in kidney transplantation to desensitize highly sensitized patients. Because it is used in a narrow, high-cost clinical scenario, Aetna requires prior authorization (PA) before it will cover the drug. A PA denial typically means either that the request was incomplete, that the submitted documentation did not satisfy Aetna's clinical criteria, or that the criteria themselves were applied incorrectly to your case.

## Why This Denial Is Appealable

A prior-authorization denial is not a final answer — it is the beginning of a structured appeal process. The denial notice must state the specific clinical reason the PA was rejected and cite the coverage policy or criterion that was not met. If the notice is vague, request the specific clinical rationale in writing. Under ERISA §503, self-funded employer plans must provide a full and fair review. Under ACA §2719, non-grandfathered insured plans must offer independent external review if internal appeals fail.

## Federal Appeal Framework

• Internal appeal: File within the deadline stated on your denial notice (typically 180 days for standard, shorter for urgent). Aetna must decide a standard appeal within 30 days for pre-service (prospective) denials.
• Urgent/expedited: If the transplant is imminent or delay would seriously jeopardize health, request expedited review — Aetna must respond within 72 hours.
• External review: If the internal appeal is denied, escalate to independent external review under ACA §2719 or your state's external review law. A neutral, Aetna-independent clinician reviews the case.
• State insurance department complaint: File simultaneously with your state regulator to create a documented record.

## Documentation to Gather

• Transplant center records: Documentation that the treating transplant program has evaluated and approved imlifidase as part of the desensitization protocol for this patient.
• Sensitization documentation: Crossmatch results, panel reactive antibody (PRA) testing, and HLA antibody profiles — your transplant nephrologist will know which records are relevant; do not rely on this guide for specific thresholds.
• Prescriber letter of medical necessity: A detailed letter from the transplant physician explaining the indication, why the patient meets criteria per the FDA-approved prescribing information and applicable transplant society guidelines, and why no alternative approach is adequate.
• Prior treatment history: Documentation of any prior desensitization attempts, dialysis duration, and prior transplant evaluations.
• Aetna clinical policy bulletin (CPB): Request the exact CPB Aetna applied. Build your appeal to answer every criterion listed in that document with specific chart evidence.

## Criteria-Mapping Structure

Once you have Aetna's CPB, map each requirement to a chart fact:

| Aetna CPB Criterion | Your Documentation | |---|---| | Confirmed indication per FDA label | Transplant program notes + diagnosis | | Sensitization level documented | PRA/HLA records | | Prescriber is a qualified transplant specialist | Credentialing information | | No adequate alternative | Prescriber letter addressing alternatives | | Consistent with society guidelines | Guideline citation from treating physician |

A point-by-point rebuttal that leaves no criterion unanswered is the most effective format for a PA appeal at Aetna.